Condition: Localized Pancreatic Adenocarcinoma · Borderline Resectable Pancreatic Adenocarcinoma · Resectable Pancreatic Adenocarcinoma · Sponsor: Amsterdam UMC, location VUmc
Since patients with (borderline) resectable pancreatic cancer have a limited life expectancy, it is important to improve treatment strategies. Therefore, the objective of this study is to investigate whether neoadjuvant triple treatment with chemotherapy (mFOLFIRINOX), immunotherapy (pembrolizumab and stereotactic radiotherapy, followed by adjuvant surgery and chemotherapy and immunotherapy, improves survival in patients with (borderline) resectabel pancreatic cancer.
This description comes directly from the study's public registry record.
J. W. Wilmink, MD, PhD · +31 204444321 · j.w.wilmink@amsterdamumc.nl
A. M. Gehrels, MD, MA · a.gehrels@amsterdamumc.nl
Always discuss trial participation with your own doctor first.
| Amsterdam University Medical Center | Amsterdam, Netherlands | Recruiting |
| Maastricht University Medical Center | Maastricht, Netherlands | Not Yet Recruiting |
| St. Antonius Ziekenhuis | Nieuwegein, Netherlands | Recruiting |
| Erasmus University Medical Center | Rotterdam, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06384560